Rodin Therapeutics Appoints CEO
This article was originally published in Scrip
Rodin Therapeutics has appointed Adam J. Rosenberg CEO and a member of its board. Rosenberg is the co-founder of various companies including Clean Membranes, where he was also on the board; Faber Law Group; and most recently, Teleos Therapeutics for which he was also director and CEO. He has also served in interim executive roles with various healthcare and biotech companies including Brightstar (acquired by SoftBank), and served on the advisory board of Gecko Health Innovations (acquired by Teva Pharmaceuticals).
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.